Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study.

Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study. J Clin Pathol. 2020 Dec 04;: Authors: Iaccarino A, Pisapia P, Pepe F, Sgariglia R, Nacchio M, Russo G, Gragnano G, De Luca C, Troncone G, Malapelle U Abstract V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene mutations have recently been approved to select advanced stages non-small cell lung cancer (NSCLC) patients for tyrosine kinase inhibitors treatments. In this setting, liquid biopsy may represent a valuable option for BRAF mutational testing in patients without tissue availability. Here, we reviewed 196 plasma based liquid biopsies analysed by an in-house developed next generation sequencing panel, termed SiRe. On the overall, 6 (3.1%) out of 196 BRAF mutated cases were identified, with an overall median allelic frequency of 3.4%. Exon 15 p.V600E was the most common detected mutation (2/6, 33.3%). Our data highlighted that the SiRe panel is a robust tool for BRAF mutation assessment on circulating tumour DNA. Further investigation is required to develop a diagnostic algorithm to harmonise BRAF testing on tissue and blood in advanced stages NSCLC patients. PMID: 33277344 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Pathol Source Type: research